FEB 03, 2016 10:30 AM PST

Assessment of animal welfare risks for externalized animal studies by partnering diligence and scientific review at GlaxoSmithKline

Speaker
  • Director, Office of Animal Welfare, Ethics and Strategy, GlaxoSmithKline
    Biography
      Mary Ann Vasbinder, DVM, DACLAM works in the Office Animal Welfare, Ethics and Strategy at GlaxoSmithKline in King of Prussia, PA. She is responsible for the team providing oversight of animal studies conducted on behalf of GSK external to the company. The other piece of her work includes strategic planning for national advocacy efforts through work with organizations such as the IQ Institutional Official Consortium (IOC), Americans for Medical Progress, One Health Research and collaborations with European and Asian partners. Mary Ann received her veterinary degree from the University of Florida in 1995. She attended a residency training program at North Carolina State University from 1995-1997. She served as the Attending Veterinarian at GlaxoSmithKline (GSK) for the Research Triangle Park program from 2006-2010. Her professional interests lie in animal housing, global animal care and use programs, animal behavior, enrichment, training and advancement of US 3Rs strategies.

    Abstract

    Animal studies performed on behalf of GlaxoSmithKline (GSK) are expected to uphold the core principles established by Corporate Policy 403, ‘Care, Welfare and Treatment of Animals by GSK’.  There are two major considerations that are assessed prior to approval of an external institution; conformance with all 8 principles for animal care and use, and an assurance of a scientific peer review.   The diligence reviews are composed of a set of electronic forms that are completed by the GSK scientists and the partnering external institution.  These forms include information about the institution, aspects of ethical review and details of the study.  Specific review is weighted based on species order, the regulatory oversight in the country of work, the level of pain/distress in the study design and any previous history with the institution.  Studies involving unalleviated pain, plus any study involving non-rodent species are forwarded to the team of expert scientists that provide a peer review.  The need for a site visit is determined by a risk rating tool that highlights the potential welfare concerns for the company.  Partnering these two processes, diligence and scientific review, meets the expectations for quality and risk assessment for external institutions at GSK.

    Learning Objectives:
    •    To understand the perceived animal welfare risks that externalized studies pose for GSK
    •    To understand the components and process of the diligence and scientific reviews 
    •    To share our risk rating tool for determination of necessary site visits


    Show Resources
    You May Also Like
    SEP 10, 2020 9:00 AM PDT
    C.E. CREDITS
    SEP 10, 2020 9:00 AM PDT
    Date: September 10, 2020 Time: 9:00am (PDT), 12:00pm (EDT) Osmolality testing is relevant throughout the entire bioprocessing workflow. As customers look to refine mAb and gene therapy workf...
    NOV 18, 2020 8:00 AM PST
    C.E. CREDITS
    NOV 18, 2020 8:00 AM PST
    DATE: November 18, 2020 TIME: 08:00am PDT We develop and implement technologies to solve some of the major bottlenecks in biomedical research. In particular, we establish new imaging approac...
    NOV 10, 2020 7:00 AM PST
    C.E. CREDITS
    NOV 10, 2020 7:00 AM PST
    DATE: November 10, 2020 TIME: 7:00am PDT, 10:00am EDT Automation can provide tremendous benefits such as increased pipetting precision and accuracy, productivity, and throughput. Numerous wo...
    NOV 16, 2020 8:00 AM PST
    C.E. CREDITS
    NOV 16, 2020 8:00 AM PST
    Date: November 16, 2020 Time: 8:00am (PST), 11:00am (EST) CRISPR screening has become the prime discovery tool in modern biomedical research and drug discovery. At the same time, most screen...
    SEP 03, 2020 9:00 AM PDT
    C.E. CREDITS
    SEP 03, 2020 9:00 AM PDT
    DATE: September 3, 2020 TIME: 09:00am PT, 12:00pm ET xxx Learning Objectives: xxx Webinars will be available for unlimited on-demand viewing after live event. LabRoots is approved as a provi...
    C.E. CREDITS
    This drug development program is designed to create a family of broad-spectrum, pan-coronaviral drugs that respectively inhibit multiple key enzymes required for viral replication. By target...
    Loading Comments...
    Show Resources
    Attendees
    • See more